Lasa Supergenerics Limited (NSE:LASA)

India · Delayed Price · Currency is INR

6.52

-0.17 (-2.54%)

Sep 9, 2026, 3:31 PM IST

Market Cap	326.66M -38.8%
Revenue (ttm)	65.20M -95.2%
Net Income	-165.50M
EPS	-3.30
Shares Out	50.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.25 (3.67%)
Ex-Dividend Date	n/a

Volume	46,913
Open	6.71
Previous Close	6.69
Day's Range	6.45 - 6.71
52-Week Range	5.67 - 14.08
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, s... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2016

Employees 66

Stock Exchange National Stock Exchange of India

Ticker Symbol LASA

Full Company Profile

Financial Performance

In fiscal year 2026, Lasa Supergenerics's revenue was 253.41 million, a decrease of -82.82% compared to the previous year's 1.47 billion. Losses were -340.90 million, 131.0% more than in 2025.

Financial Statements